HER-2 expression

AI-assisted HER2 IHC scoring significantly improves interobserver consistency and provides quantitative support that helps address key limitations of conventional categorical HER2 assessment.

P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2030 | Trial primary completion date: May 2023 --> Dec 2029

P1/2, N=380, Recruiting, BioNTech SE | Trial completion date: May 2029 --> Aug 2029 | Trial primary completion date: May 2028 --> Aug 2029

P1, N=27, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting

T. gondii infection is highly prevalent in female patients with breast tumors and is correlated with specific environmental exposures and clinicopathologic features of tumor invasiveness. This robust predictive model can be used accurately and reliably for individualized risk assessment of T. gondii infection in women with breast tumors. It can assist clinicians in developing targeted screening and intervention plans, maximizing clinical benefits while reducing unnecessary diagnostic and treatment procedures.

Our findings exposit that the higher 2-GMGs expression and the worse progression and prognosis of HCC. The SHAP approach was employed to elucidate the 2-GMGs model, enhancing its utility for clinicians.

The incidence of brain metastases in each group were 0 (0/3), 33.33% (39/117), 74.55% (82/110) and 100.00% (17/17), respectively. The risk stratification of brain metastasis based on clinicopathological characteristics and levels of related tumor markers are helpful to predict the risk of brain metastasis in non-stage Ⅳ breast cancer patients with HER-2 low expression after systematic treatment, so as to accurately identify patients with high recurrence risk and formulate targeted follow-up strategies for them.

The FROC model could help identify the low Ki67 expression (≤ 5%) and prevent unnecessary chemotherapy.

Multiplexed imaging showed broad but heterogeneous HER2 expression across tumor states in both cases; in the MYCN-amplified tumor, this occurred alongside EGFR/MAPK-enriched proliferative niches, whereas the ZFTA-RELA tumor showed more diffuse organization without strong coupling of EGFR and proliferation. These findings provide early clinical evidence supporting HER2-directed ADCs in ependymoma and highlight the value of integrated molecular and spatial profiling in interpreting therapeutic response in rare CNS tumors.

BCL2 can serve as a useful prognostic marker and merits inclusion in the routine IHC panel for breast cancer, as it may contribute to the development of individualized, tailored therapeutic strategies.

Using a blinded test set of 412 unique tissue samples, our approach achieved a testing accuracy of 84.9% for 4-class (0, 1+, 2+, 3+) HER2 classification and 94.8% for binary (0/1+ versus 2+/3+) HER2 scoring with uncertainty quantification. This lensfree holography approach provides a practical pathway toward high-throughput, cost-effective HER2 scoring, particularly suited for resource-limited settings where traditional digital pathology infrastructure is unavailable.

Bax expression levels were lower in the tumour group and the B. multiflora extract-treated groups than in the control group. The absence of the apoptotic and/or cytotoxic effects observed in previous studies involving Bryonia species in this study may be due to several factors. Similar studies should be conducted in the future to further understand the various therapeutic effects of plants.